Exelixis, Swedish Orphan Biovitrum Enter Three-Year Agreement for Distribution and Commercialization of COMETRIQ for MTC in EU

Exelixis, Inc.

and Swedish Orphan Biovitrum (Sobi)

today announced that they have entered into a three-year agreement to support the distribution and commercialization of COMETRIQ(TM) (cabozantinib) for metastatic medullary thyroid cancer (MTC) in the European Union (EU) and potentially other countries.  No other indication is covered by this agreement, and Exelixis maintains full commercial rights for COMETRIQ in MTC outside the covered territory and for all other indications on a global basis. On November 29, 2012, Exelixis announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for COMETRIQ for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic MTC. "We are pleased to be working with Sobi to distribute and commercialize COMETRIQ for MTC in the EU, while at the same time maintaining commercial rights for all other oncology indications on a global basis," said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. "By